BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:56 PM | Browse: 389 | Download: 1220
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 101371
Country China
ISSN 1948-5204 (online)
Open Access Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Immunology
Manuscript Type Retrospective Study
Article Title Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Jian-Lin Lu, Yuan Cheng, Zi-Ling Xu, Gui-Xiang Qian, Ming-Tong Wei and Wei-Dong Jia
ORCID
Author(s) ORCID Number
Jian-Lin Lu http://orcid.org/0009-0009-4466-0565
Yuan Cheng http://orcid.org/0000-0002-7081-4160
Zi-Ling Xu http://orcid.org/0009-0007-4487-9415
Gui-Xiang Qian http://orcid.org/0000-0002-3971-7258
Ming-Tong Wei http://orcid.org/0009-0001-3894-4125
Wei-Dong Jia http://orcid.org/0009-0008-1419-3401
Funding Agency and Grant Number
Funding Agency Grant Number
Key Research and Development Projects of Anhui Province 202104j07020048
National Key Research and Development Program of China 2022YFA1304504
Corresponding Author Wei-Dong Jia, MD, PhD, Professor, Department of Hepatic Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. jwd1968@ustc.edu.cn
Key Words Hepatocellular carcinoma; Hepatitis B virus; Postoperative adjuvant therapy; Immune checkpoint inhibitors; Anti-angiogenesis
Core Tip The postoperative combined therapy with anti-programmed death 1/anti-programmed death ligand 1 and anti-vascular endothelial growth factor receptor agents has not been shown to be effective but not significant in reducing early recurrence in patients with hepatitis B virus-associated hepatocellular carcinoma. And thorough evaluation and close monitoring of liver function and hepatitis B-related markers in patients with hepatitis B virus-associated hepatocellular carcinoma are critical when implementing this combined treatment approach.
Publish Date 2025-03-25 16:18
Citation

Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 101371

URL https://www.wjgnet.com/1948-5204/full/v17/i4/101371.htm
DOI https://dx.doi.org/10.4251/wjgo.v17.i4.101371
Full Article (PDF) WJGO-17-101371-with-cover.pdf